Wednesday, 29 April 2020

IPCA asks USFDA to clarify on Hydroxychloroquine risk

Hydroxychloroquine, besides being administered as an anti-malarial
drug, is also used as a chronic therapy by patients suffering from
auto immune diseases such as RA and Lupus. In the recent months the
drug has been used in several countries including India and US in the
treatment of critically ill Covid-19 patients.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/ipca-asks-usfda-to-clarify-on-hydroxychloroquine-risk/articleshow/75462945.cms

No comments:

Post a Comment